Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have been shown to improvethe outcome of patients with HF, but patients with ATTR-CA have been excludedfrom all phase III trials on empagliflozin and dapagliflozin [61, 62, 63]. This evidence concerns the gene SLC5A2 and hydrops fetalis.